CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 157 enrolled
Drug / intervention
Ulipristal acetate (UPA) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02147197
NCT02147197Phase 3Completed
CompareCT.gov

A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Allergan·interventional·Posted May 26, 2014·Updated Apr 30, 2019

In Brief

A Phase 3 clinical trial evaluating Ulipristal acetate (UPA) and Placebo for Leiomyoma and Uterine Hemorrhage. Completed, enrolled 157 participants across 28 sites.

Detailed Summary

This study will evaluate the superiority of ulipristal acetate versus placebo for the treatment of abnormal uterine bleeding associated with uterine fibroids

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeiomyoma, Uterine Hemorrhage
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 26, 2014
Enrollment StartMar 31, 2014
Primary CompletionMar 29, 2016
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 12.1 years ago

Interventions

Ulipristal acetate (UPA)drug

UPA tablet

Placebodrug

Matching placebo tablet.